The Rollings Cancer Center (HCC) Clinical Trials Office (CTO) provides a centralized office for the conduct of cancer clinical trials at the Medical University of South Carolina (MUSC). The purpose of the HCC CTO is to provide an effective and efficient clinical research infrastructure to support investigators and clinicians in developing and implementing clinical research studies. The major functions of the CTO are to: Assist HCC Principal Investigators in the activation and administration of studies, including the preparations and communications required for scientific, ethical, financial and operational reviews as well as ongoing support for annual regulatory reviews Assist clinicians in screening and enrolling patients for clinical research studies Coordinate and ensure the completion of patient-specific study requirements Provide data management support for clinical research studies Prepare medical and research records for internal and external quality and compliance audits Provide training and education pertaining to the best practices in conducting clinical studies to clinical and CTO staff as well as new investigators Communicate the availability of clinical studies to HCC physicians, referring physicians and the public Administer the HCC Clinical Trials Network, which promotes statewide clinical trial access Over the past decade the CTO has expanded its capacity, services and capabilities and is considered one of MUSC's most effective and efficient clinical research units. Currently, the HCC CTO provides services to twenty-one MUSC departments/divisions and the clinical trials portfolio includes studies from all of the major NCI Cooperative Group trials (e.g., SWOG, RTOG, GOG, COG, ACRIN, ACoSOG, NSABP), industry sponsored studies and a growing number of investigator-initiated studies. Accrual to therapeutic clinical trials has quadrupled during the past five years and now represents 11% of total new HCC cancer cases.
The HCC Clinical Trials Office provides key services that: 1) promote awareness of clinical studies and their importance to the future development of new therapies;2) ensure effective and efficient administration of clinical studies;and 3) facilitate the capture of information needed to disseminate the results of clinical studies.
|Link, Laura A; Howley, Breege V; Hussey, George S et al. (2016) PCBP1/HNRNP E1 Protects Chromosomal Integrity by Translational Regulation of CDC27. Mol Cancer Res 14:634-46|
|Nelson, Michelle H; Bowers, Jacob S; Bailey, Stefanie R et al. (2016) Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8(+) T cells without host preconditioning. J Immunother Cancer 4:6|
|Podbielska, Maria; Szulc, ZdzisÅ‚aw M; Kurowska, Ewa et al. (2016) Cytokine-induced release of ceramide-enriched exosomes as a mediator of cell death signaling in an oligodendroglioma cell line. J Lipid Res 57:2028-2039|
|Sambandam, Yuvaraj; Sakamuri, Sashank; Balasubramanian, Sundaravadivel et al. (2016) RANK Ligand Modulation of Autophagy in Oral Squamous Cell Carcinoma Tumor Cells. J Cell Biochem 117:118-25|
|Miller, Kayla; Dixit, Suraj; Bredlau, Amy-Lee et al. (2016) Delivery of a drug cache to glioma cells overexpressing platelet-derived growth factor receptor using lipid nanocarriers. Nanomedicine (Lond) 11:581-95|
|Basher, Fahmin; Jeng, Emily K; Wong, Hing et al. (2016) Cooperative therapeutic anti-tumor effect of IL-15 agonist ALT-803 and co-targeting soluble NKG2D ligand sMIC. Oncotarget 7:814-30|
|Small, James; Flanagan, Catherine; Armeson, Kent et al. (2016) Family history of cutaneous and noncutaneous malignancies in relation to the risk of keratinocyte carcinoma coupled with another type of cancer: A case-control study. J Am Acad Dermatol 75:1066-1068.e7|
|Maldonado, Eduardo N; DeHart, David N; Patnaik, Jyoti et al. (2016) ATP/ADP Turnover and Import of Glycolytic ATP into Mitochondria in Cancer Cells Is Independent of the Adenine Nucleotide Translocator. J Biol Chem 291:19642-50|
|Hendriks, Giel; Derr, Remco S; Misovic, Branislav et al. (2016) The Extended ToxTracker Assay Discriminates Between Induction of DNA Damage, Oxidative Stress, and Protein Misfolding. Toxicol Sci 150:190-203|
|Paul, Matt R; Levitt, Nicholas P; Moore, David E et al. (2016) Multivariate models from RNA-Seq SNVs yield candidate molecular targets for biomarker discovery: SNV-DA. BMC Genomics 17:263|
Showing the most recent 10 out of 311 publications